CO6270370A2 - Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 - Google Patents

Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8

Info

Publication number
CO6270370A2
CO6270370A2 CO10043417A CO10043417A CO6270370A2 CO 6270370 A2 CO6270370 A2 CO 6270370A2 CO 10043417 A CO10043417 A CO 10043417A CO 10043417 A CO10043417 A CO 10043417A CO 6270370 A2 CO6270370 A2 CO 6270370A2
Authority
CO
Colombia
Prior art keywords
antibody
vegf
fragment
antagonist
angiogenesis
Prior art date
Application number
CO10043417A
Other languages
English (en)
Spanish (es)
Inventor
Napoleone Ferrara
Farbod Shojaei
Cuiling Zhong
Xiumin Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CO6270370A2 publication Critical patent/CO6270370A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
CO10043417A 2007-09-21 2010-04-14 Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 CO6270370A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97438207P 2007-09-21 2007-09-21
US8307108P 2008-07-23 2008-07-23

Publications (1)

Publication Number Publication Date
CO6270370A2 true CO6270370A2 (es) 2011-04-20

Family

ID=40030248

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10043417A CO6270370A2 (es) 2007-09-21 2010-04-14 Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8

Country Status (19)

Country Link
US (1) US9284369B2 (cg-RX-API-DMAC10.html)
EP (1) EP2203479B1 (cg-RX-API-DMAC10.html)
JP (1) JP5615709B2 (cg-RX-API-DMAC10.html)
KR (1) KR101578945B1 (cg-RX-API-DMAC10.html)
CN (1) CN102037015B (cg-RX-API-DMAC10.html)
AR (1) AR068532A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008302214B2 (cg-RX-API-DMAC10.html)
CA (1) CA2700276A1 (cg-RX-API-DMAC10.html)
CL (1) CL2008002782A1 (cg-RX-API-DMAC10.html)
CO (1) CO6270370A2 (cg-RX-API-DMAC10.html)
ES (1) ES2568881T3 (cg-RX-API-DMAC10.html)
IL (1) IL204502A (cg-RX-API-DMAC10.html)
MX (1) MX2010003013A (cg-RX-API-DMAC10.html)
NZ (1) NZ584787A (cg-RX-API-DMAC10.html)
PE (1) PE20091197A1 (cg-RX-API-DMAC10.html)
RU (2) RU2471498C2 (cg-RX-API-DMAC10.html)
TW (1) TWI457349B (cg-RX-API-DMAC10.html)
WO (1) WO2009039337A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201001868B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100942880B1 (ko) * 2001-08-29 2010-02-17 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
JP2010519907A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｖｅｇｆファミリー遺伝子の発現を抑制するための核酸化合物およびその使用
ES2513292T3 (es) 2009-07-31 2014-10-24 Genentech, Inc. Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
AU2010313621C1 (en) 2009-10-14 2015-11-26 Humanigen, Inc. Antibodies to EphA3
MX2012007379A (es) * 2009-12-23 2012-08-31 Genentech Inc Anticuerpos anti-bv8 y usos de los mismos.
WO2011103389A1 (en) * 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
JP2014525412A (ja) * 2011-08-17 2014-09-29 ジェネンテック， インコーポレイテッド 難治性腫瘍における血管新生の阻害
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
US20150118215A1 (en) * 2012-03-30 2015-04-30 The General Hospital Corporation Methods of Inhibiting Cell Proliferation
TWI498425B (zh) * 2013-01-08 2015-09-01 Nat Univ Tsing Hua 層析濾紙型酵素連結免疫吸附分析法
US20160030558A1 (en) * 2013-03-13 2016-02-04 Health Research, Inc. Enhancement of vaccines
KR102359396B1 (ko) * 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN104237223B (zh) * 2014-10-08 2017-04-12 江苏奥赛康药业股份有限公司 测定铁‑碳水化合物络合物中不稳定铁含量的方法
CN104587469A (zh) * 2015-01-19 2015-05-06 马洁 G-csf拮抗剂在治疗慢性炎症、预防炎症相关肿瘤中的应用
WO2017096124A1 (en) * 2015-12-03 2017-06-08 National Health Research Institutes Heterodimeric vascular endothelial growth factor and use thereof
WO2018108862A1 (en) * 2016-12-12 2018-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer
US20210179721A1 (en) * 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
CN115768475A (zh) 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4739706A1 (en) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
KR100942880B1 (ko) * 2001-08-29 2010-02-17 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CN102225194B (zh) * 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
CN1802169A (zh) * 2003-03-12 2006-07-12 健泰科生物技术公司 Bv8和/或EG－VEGF促进造血的用途
RS20150135A1 (sr) * 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
ITRM20070182A1 (it) 2007-04-03 2008-10-04 Univ Roma Antagonisti dei recettori delle prochineticine derivati di essi e loro uso

Also Published As

Publication number Publication date
EP2203479A2 (en) 2010-07-07
RU2010115755A (ru) 2011-10-27
US20100316633A1 (en) 2010-12-16
EP2203479B1 (en) 2016-01-27
KR101578945B1 (ko) 2015-12-21
TWI457349B (zh) 2014-10-21
IL204502A (en) 2015-05-31
CA2700276A1 (en) 2009-03-26
TW200920750A (en) 2009-05-16
RU2471498C2 (ru) 2013-01-10
CL2008002782A1 (es) 2009-07-31
AR068532A1 (es) 2009-11-18
RU2012140185A (ru) 2014-03-27
WO2009039337A3 (en) 2009-05-14
HK1141538A1 (zh) 2010-11-12
CN102037015A (zh) 2011-04-27
ES2568881T3 (es) 2016-05-05
JP5615709B2 (ja) 2014-10-29
ZA201001868B (en) 2011-06-29
JP2010540449A (ja) 2010-12-24
PE20091197A1 (es) 2009-08-14
NZ584787A (en) 2012-12-21
CN102037015B (zh) 2016-02-03
AU2008302214B2 (en) 2012-10-25
MX2010003013A (es) 2010-08-02
AU2008302214A1 (en) 2009-03-26
WO2009039337A2 (en) 2009-03-26
KR20100075513A (ko) 2010-07-02
US9284369B2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20091197A1 (es) ANTAGONISTAS Bv8 COMO INHIBIDORES DE ANGIOGENESIS
MX384227B (es) Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis.
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
EA201170157A1 (ru) Notch-связывающие агенты и антагонисты и способы их применения
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
AR066850A1 (es) Dominio variable simple de inmunoglobulina contra el factor de crecimiento endotelial vascular (vegf)
PE20191131A1 (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
NZ626665A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
CO6440535A2 (es) Antagonistas especificos del receptor fgf-r4
MY149630A (en) Antibodies against amyloid-beta peptide
UA94899C2 (ru) Фиксированное дозирование антител к her
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
AR070821A1 (es) Anticuerpo anti- tyrp1 (antitiroxina humana)
JP2009522316A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
FC Application refused